Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology’s Annual Scientific Session.
Climate change heat poses lasting brain risks for children, study finds
The impact of temperature exposure on children’s mental health and cognition during prenatal and early childhood periods.
June 14, 2024